<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881111405556</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881111405556</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>D1 and D2 dopaminergic systems in the rat basolateral amygdala are involved in anxiogenic-like effects induced by histamine</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Bananej</surname><given-names>Maryam</given-names></name>
<xref ref-type="aff" rid="aff1-0269881111405556">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Karimi-Sori</surname><given-names>Ahmad</given-names></name>
<xref ref-type="aff" rid="aff1-0269881111405556">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zarrindast</surname><given-names>Mohammad Reza</given-names></name>
<xref ref-type="aff" rid="aff2-0269881111405556">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ahmadi</surname><given-names>Shamseddin</given-names></name>
<xref ref-type="aff" rid="aff3-0269881111405556">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0269881111405556"><label>1</label>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran</aff>
<aff id="aff2-0269881111405556"><label>2</label>Department of Neuroscience, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran, Iran</aff>
<aff id="aff3-0269881111405556"><label>3</label>Department of Biological Science and Biotechnology, Faculty of Science, University of Kurdistan, Sanandaj, Iran</aff>
<author-notes>
<corresp id="corresp1-0269881111405556">S Ahmadi, Department of Biological Sciences and Biotechnology, Faculty of Science, University of Kurdistan, P.O. Box 66167-15145, Sanandaj, Iran Email: <email>sh.ahmadi@uok.ac.ir</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>4</issue>
<fpage>564</fpage>
<lpage>574</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Involvement of the dopamine receptors in the basolateral amygdala (BLA) in the effects of histamine on anxiety-like behaviors of the elevated plus maze in male Wistar rats was investigated. The results showed that bilateral intra-BLA injections of histamine (2.5, 5 and 7.5 µg/rat) induced an anxiogenic-like effect, revealed by decreases in percentage of open arm time (%OAT) and open arm entries (%OAE). Intra-BLA administration of dopamine D1 receptor agonist, SKF38393 (0.25 µg/rat), and dopamine D2 receptor agonist, quinpirole (0.03 and 0.05 µg/rat), decreased %OAT but not %OAE. Conversely, intra-BLA administration of dopamine D1 receptor antagonist, SCH23390 (0.5 and 1 µg/rat), and dopamine D2 receptor antagonist, sulpiride (0.3 and 0.5 µg/rat), increased %OAT and %OAE, suggesting an anxiolytic-like effect for both drugs. Interestingly, co-administration of a silent dose of SCH23390 or sulpiride prevented anxiogenic-like effects of SKF38393 and quinpirole, respectively. Conjoint administration of a sub-effective dose of SKF38393 (0.125 µg/rat) or quinpirole (0.01 µg/rat) along with lower doses of histamine (1 and 2.5 µg/rat) induced anxiolytic-like effects. On the other hand, intra-BLA pretreatment with a silent dose of SCH23390 (0.25 µg/rat) or sulpiride (0.1 µg/rat) prevented the anxiogenic-like effect of higher doses of histamine (5 and 7.5 µg/rat). No significant change was observed in total closed arm entries, as an index for motor activity of the animals. It can be concluded that the dopamine D1 and D2 receptors in the BLA may be involved in the anxiogenic-like effects induced by histamine.</p>
</abstract>
<kwd-group>
<kwd>Anxiety</kwd>
<kwd>histamine</kwd>
<kwd>elevated plus maze</kwd>
<kwd>quinpirole</kwd>
<kwd>SCH23390</kwd>
<kwd>SKF38393</kwd>
<kwd>sulpiride</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881111405556" sec-type="intro">
<title>Introduction</title>
<p>The amygdala has been accepted as an important site for the regulation of anxiety (for reviews see <xref ref-type="bibr" rid="bibr27-0269881111405556">Phelps and LeDoux, 2005</xref>; <xref ref-type="bibr" rid="bibr33-0269881111405556">Sah et al., 2003</xref>). The amygdaloid complex can be subdivided into essentially two sub-territories, the central amygdala (CeA) and basolateral amygdala (BLA). The central nucleus is the principle region for projections to hindbrain areas coordinating the behavioral, autonomic and endocrine response to fear. The BLA is the major region for direct receipt of sensory and other modes of input from the thalamus and parabrachial nucleus, and indirect input from the cortex (for reviews see <xref ref-type="bibr" rid="bibr7-0269881111405556">Davis et al., 1994</xref>; <xref ref-type="bibr" rid="bibr20-0269881111405556">LeDoux, 2000</xref>; <xref ref-type="bibr" rid="bibr22-0269881111405556">Millan, 2003</xref>; <xref ref-type="bibr" rid="bibr37-0269881111405556">Swanson and Petrovich, 1998</xref>).</p>
<p>Anatomical data have shown that the BLA receives dopaminergic afferents originating from the ventral tegmental area (VTA) and glutamatergic afferents from the medial prefrontal cortex (mPFC). The BLA also sends glutamatergic projections to the VTA and the mPFC. Glutamatergic excitatory axon terminals originating from the mPFC to GABAergic interneurons in the amygdala are presynaptically inhibited by dopaminergic afferents from the VTA (for detailed information see <xref ref-type="bibr" rid="bibr1-0269881111405556">Amaral and Corbett, 2003</xref>; <xref ref-type="bibr" rid="bibr36-0269881111405556">Swanson, 1982</xref>; <xref ref-type="bibr" rid="bibr37-0269881111405556">Swanson and Petrovich, 1998</xref>; <xref ref-type="bibr" rid="bibr44-0269881111405556">Zahm and Trimble, 2008</xref>). The amygdala also receives histaminergic afferents derived from the tuberomammillary nucleus of the hypothalamus (<xref ref-type="bibr" rid="bibr12-0269881111405556">Haas and Panula, 2003</xref>; <xref ref-type="bibr" rid="bibr23-0269881111405556">Panula et al., 1989</xref>; <xref ref-type="bibr" rid="bibr25-0269881111405556">Passani et al., 2007</xref>). High densities of histamine H1, H2 and H3 receptors have been identified within the BLA (<xref ref-type="bibr" rid="bibr4-0269881111405556">Brown et al., 2001</xref>; <xref ref-type="bibr" rid="bibr12-0269881111405556">Haas and Panula, 2003</xref>; <xref ref-type="bibr" rid="bibr13-0269881111405556">Haas et al., 2008</xref>).</p>
<p>Histamine and histaminergic systems have been shown to be involved in the modulation of anxiety-like behaviors (<xref ref-type="bibr" rid="bibr21-0269881111405556">Malmberg-Aiello et al., 2002</xref>; <xref ref-type="bibr" rid="bibr29-0269881111405556">Privou et al., 1998</xref>). It has been shown that various stressful situations such as restraint, cold stress and foot shock increase the turnover of histamine in the rodent brain (<xref ref-type="bibr" rid="bibr38-0269881111405556">Taylor and Snyder, 1971</xref>; <xref ref-type="bibr" rid="bibr43-0269881111405556">Yoshitomi et al., 1986</xref>). <xref ref-type="bibr" rid="bibr19-0269881111405556">Ito et al. (1999)</xref> reported that acute and chronic restraint stresses increased the brain histamine turnover. Studies using local administration of histamine into the CeA and BLA have also reported anxiogenic-like effects for the drug in the elevated plus maze (<xref ref-type="bibr" rid="bibr14-0269881111405556">Hajizadeh Moghaddam et al., 2008</xref>; <xref ref-type="bibr" rid="bibr46-0269881111405556">Zarrindast et al., 2005a</xref>).</p>
<p>Dopamine is another of the neuromodulators most active in the mechanisms underlying states of fear and anxiety (<xref ref-type="bibr" rid="bibr3-0269881111405556">Brandao et al., 1999</xref>; <xref ref-type="bibr" rid="bibr20-0269881111405556">LeDoux, 2000</xref>; <xref ref-type="bibr" rid="bibr32-0269881111405556">Rodgers et al., 1994</xref>; <xref ref-type="bibr" rid="bibr44-0269881111405556">Zahm and Trimble, 2008</xref>). A well-established stress-responsive role has been reported for mesocortical and mesolimbic dopaminergic pathways originating from the VTA (<xref ref-type="bibr" rid="bibr15-0269881111405556">Homberg et al., 2002</xref>; <xref ref-type="bibr" rid="bibr36-0269881111405556">Swanson, 1982</xref>; <xref ref-type="bibr" rid="bibr39-0269881111405556">Thiel and Schwarting, 2001</xref>). Selective activation of mesoamygdaloid dopamine neurons by conditioned stress has been reported (<xref ref-type="bibr" rid="bibr6-0269881111405556">Coco et al., 1992</xref>). It has been shown that both dopamine D1 and D2 receptor mechanisms are important in mediating anxiety (<xref ref-type="bibr" rid="bibr9-0269881111405556">de Oliveira et al., 2006</xref>; <xref ref-type="bibr" rid="bibr18-0269881111405556">Inoue et al., 2005</xref>; <xref ref-type="bibr" rid="bibr32-0269881111405556">Rodgers et al., 1994</xref>; <xref ref-type="bibr" rid="bibr41-0269881111405556">Timothy et al., 1999</xref>; <xref ref-type="bibr" rid="bibr42-0269881111405556">Tzavara et al., 2003</xref>). <xref ref-type="bibr" rid="bibr30-0269881111405556">Rezayof et al. (2009)</xref> reported that intra-CeA administration of a mixed dopamine D1/D2 receptor agonist, apomorphine, induced anxiolytic-like effects in the elevated plus maze, which was prevented by D1 or D2 dopamine receptor antagonists. Other researchers have also shown that conditioned fear, anxiety and other stressors can activate the VTA-derived dopaminergic pathways to the amygdala and adjacent bed nucleus of the stria terminals (<xref ref-type="bibr" rid="bibr6-0269881111405556">Coco et al., 1992</xref>; <xref ref-type="bibr" rid="bibr11-0269881111405556">Greba et al., 2001</xref>; <xref ref-type="bibr" rid="bibr17-0269881111405556">Inglis and Moghaddam, 1999</xref>; <xref ref-type="bibr" rid="bibr35-0269881111405556">Suzuki et al., 2002</xref>).</p>
<p>Taking these findings together, it is logical to hypothesize that the dopamine D1 and D2 receptors within the BLA may be involved in anxiety-like behaviors. The aim of the present study was to investigate the involvement of the dopaminergic systems of the BLA in the effects of histamine on anxiety-like behaviors of the elevated plus maze test in the rat. For this purpose, first the effects of intra-BLA injections of histamine, dopamine D1 and D2 receptor agonists and antagonists on anxiety-like behaviors in the elevated plus maze were examined. Then, the interactions between histamine and dopamine D1 and D2 receptor agents on anxiety-like behaviors were evaluated.</p>
</sec>
<sec id="section2-0269881111405556" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0269881111405556">
<title>Animals</title>
<p>Male Wistar rats (Pasteur Institute, Tehran, Iran) weighing 250–280 g at the time of surgery were used. Four animals were housed per cage (42 cm × 26 cm × 15 cm height) in a room with a 12/12 h light/dark cycle (lights on at 07:00) and controlled temperature (22 ± 2°C). They had free access to food and water, and were allowed to adapt to the animal house conditions for at least 1 week before the experiments. Experimental groups consisted of eight rats and each animal was tested once. All experiments were performed between 09:00 and 12:00. All procedures were performed in accordance with international guidelines for animal care and use (NIH publication #85–23, revised in 1985).</p>
</sec>
<sec id="section4-0269881111405556">
<title>Drugs</title>
<p>The drugs used in the present study were as follows: SKF38393 hydrobromide, -(−) quinpirole hydrochloride, SCH 23390 hydrochloride (Tocris, Bristol, UK), histamine dihydrochloride and (±)-sulpiride (Sigma, St. Louis, MO, USA). All drugs except for sulpiride were dissolved in sterile 0.9% saline. Sulpiride was dissolved in one drop of glacial acetic acid and made up to a volume of 2 mL with sterile 0.9% saline, and was then diluted to the required volume using saline. The drug doses and injection times were based on a pilot study and previous works (for histamine <xref ref-type="bibr" rid="bibr50-0269881111405556">Zarrindast et al., 2005c</xref>, <xref ref-type="bibr" rid="bibr53-0269881111405556">2008b</xref>, <xref ref-type="bibr" rid="bibr45-0269881111405556">2010a</xref>; for dopaminergic agents <xref ref-type="bibr" rid="bibr30-0269881111405556">Rezayof et al., 2009</xref>; <xref ref-type="bibr" rid="bibr49-0269881111405556">Zarrindast et al., 2003</xref>, <xref ref-type="bibr" rid="bibr48-0269881111405556">2005b</xref>).</p>
</sec>
<sec id="section5-0269881111405556">
<title>Surgery</title>
<p>The animals were anesthetized with an intraperitoneal injection of a ketamine/xylazine mixture (100 and 10 mg/kg, respectively) and placed in a stereotaxic frame (Stoelting Co, Illinois, USA). A midline scalp incision was made and the skin and underlying periosteum retracted. Then, two stainless steel guide cannulae (22-gauge, Supa, Iran) were implanted bilaterally 2 mm above the BLA. The coordinates for the BLA were: −2.4 mm posterior to bregma; ±5 mm lateral to the midline; and −6.6 mm ventral to the dorsal surface of the skull (<xref ref-type="bibr" rid="bibr26-0269881111405556">Paxinos and Watson, 2007</xref>). The cannulae were anchored to the skull with a jeweler’s screw and dental cement, and then two capped stainless steel stylets (27 gauge) were inserted into the guide cannulae to maintain patency prior to microinfusions. The surgery was done with maximal care to minimize infection, and the animals were housed in a clean box after surgery and were given postsurgical penicillin G-procaine treatment (5,000,000 U in 5 mL, <italic>im</italic>). After surgery, the animals were allowed 5 days of recovery before the behavioral testing. During the recovery period rats were handled for 3 min each day prior to being submitted to the elevated plus maze.</p>
</sec>
<sec id="section6-0269881111405556">
<title>Drug microinjections</title>
<p>Intra-BLA injections were performed by means of an injection cannula (27-gauge, Supa, Iran) connected by a polyethylene tube to a 1-µL Hamilton syringe. The length of the injection cannula was 2 mm longer than the guide cannulae, terminating 2 mm below the tip of the guide cannulae (−8.6 mm ventral to the dorsal surface of the skull). The animals received bilateral intra-BLA microinjections of 1 µL/rat (0.5 µL/side, bilaterally) of each solution over a 60-s period followed by an additional 60 s to allow diffusion of the solution from the tip of the injection cannula. Rate of infusion was controlled manually by the researcher, and after each injection the Hamilton microsyringe was removed, filled again and vacated onto paper to confirm drug delivery. In experiments with intra-BLA injection of one drug, it was injected 5 min prior to the rat being submitted to the behavioral testing, and in cases of two successive drugs injections the second drug was injected immediately after the first one using another Hamilton microsyringe, and testing was performed 5 min after the final microinjection. Animals were randomly allocated to treatment conditions and tested in a counterbalanced order.</p>
</sec>
<sec id="section7-0269881111405556">
<title>Elevated plus maze</title>
<p>The elevated plus maze was a Plexiglas cross-shaped maze consisting of four arms (two open arms and two closed arms), arranged in the shape of a plus sign. The open arms had no walls (50 cm × 10 cm), but a rim of Plexiglas (0.5 cm high) surrounded the perimeter of the open arms to prevent the rats from falling. The closed arms were enclosed by dark walls of 40 cm height (50 cm × 10 cm × 40 cm). Where the four arms intersected, there was a square platform of 10 cm × 10 cm without any walls. The whole apparatus was elevated 50 cm from the floor (<xref ref-type="bibr" rid="bibr46-0269881111405556">Zarrindast et al., 2005a</xref>, <xref ref-type="bibr" rid="bibr51-0269881111405556">2008a</xref>).</p>
</sec>
<sec id="section8-0269881111405556">
<title>Behavioral testing</title>
<p>At least 1 h before testing, the rats were placed in the experimental room with sound and light attenuated. During testing each rat was placed in the center of the maze facing a closed arm and allowed free exploration for 5 min. The experimental sessions were recorded by a video camera interfaced with a monitor and a VCR in an adjacent room. Videotapes were scored by a highly trained observer (intra-rater reliability ≥ 0.9) who was blind to the treatment conditions. The number of entries (with all four paws) into open and closed arms, and the total time in the open and closed arms were recorded. The percentage of open arm time (%OAT) and open arm entries (%OAE), used as the standard anxiety indices (<xref ref-type="bibr" rid="bibr31-0269881111405556">Rodgers and Johnson, 1995</xref>), were calculated using the following formulae: %OAT (the ratio of the total time spent in the open arms to the total time spent in four arms × 100); %OAE (the ratio of the total entries into the open arms to the total entries in four arms × 100). Total closed arm entries were also recorded for each rat as an index for motor activity of the animal (<xref ref-type="bibr" rid="bibr31-0269881111405556">Rodgers and Johnson, 1995</xref>).</p>
</sec>
<sec id="section9-0269881111405556">
<title>Experimental design</title>
<p>Eight rats were used in each experimental group. Total doses of the drugs were dissolved in a volume of 1 µL, so bilateral intra-BLA microinfusions of drugs were in a volume of 1 µL/rat or 0.5 µL per each side. Control groups received vehicle (1 µL/rat or 0.5 µL per each side, bilaterally), and whenever the drug was dissolved in saline, the vehicle used was saline.</p>
<sec id="section10-0269881111405556">
<title>Experiment 1: Effect of intra-BLA injections of histamine on anxiety-like behaviors in the elevated plus maze</title>
<p>Five groups of animals were used in this experiment, and received intra-BLA injections of saline or histamine at the different doses (1, 2.5, 5 and 7.5 µg/rat).</p>
</sec>
<sec id="section11-0269881111405556">
<title>Experiment 2: Effect of intra-BLA injections of dopamine D1 and D2 receptor agonists, SKF38393 and quinpirole, respectively on anxiety-like behaviors</title>
<p>Eight groups of rats were used in this experiment. Four groups of them received intra-BLA injections of saline or SKF38393 at the different doses (0.05, 0.125, and 0.25 µg/rat). The other four groups of rats received saline or quinpirole at the different doses (0.25, 0.5 and 1 µg/rat).</p>
</sec>
<sec id="section12-0269881111405556">
<title>Experiment 3: Effect of intra-BLA injections of dopamine D1 and D2 receptor antagonists, SCH23390 and sulpiride, respectively, on anxiety-like behaviors</title>
<p>Eight groups of rats were used in this experiment. Four groups of them received intra-BLA injections of saline or SCH23390 at the different doses (0.25, 0.5 and 1 µg/rat). The other four groups of rats received intra-BLA injections of saline or sulpiride at the different doses (0.1, 0.3 and 0.5 µg/rat).</p>
</sec>
<sec id="section13-0269881111405556">
<title>Experiment 4: Effect of dopamine receptors in the BLA on anxiety-like behaviors</title>
<p>Six groups of animals were used in this experiment, and received intra-BLA injections of silent doses of dopamine receptor antagonists before their agonists. Three groups of animals received intra-BLA injections of SCH23390 (0.25 µg/rat) plus saline or SKF38393 (0.125 or 0.25 µg/rat). The other three groups received intra-BLA injections of sulpiride (0.1 µg/rat) plus saline or quinpirole (0.03 or 0.05 µg/rat).</p>
</sec>
<sec id="section14-0269881111405556">
<title>Experiment 5: Possible interaction between intra-BLA injections of histamine and dopamine receptor agonists on anxiety-like behaviors</title>
<p>Nine groups of animals were used, divided into three sets of three groups. Each set of animals received saline or histamine (1 or 2.5 µg/rat) as the first injection, plus saline (1 µL/rat) or SKF38393 (0.05 µg/rat) or quinpirole (0.01 µg/rat), respectively, as the second injection for each set.</p>
</sec>
<sec id="section15-0269881111405556">
<title>Experiment 6: Possible interaction between intra-BLA injections of histamine and dopamine receptor antagonists on anxiety-like behaviors</title>
<p>Twelve groups of animals were used, divided into three sets of four groups. Each set of animals received saline or histamine (2.5, 5 and 7.5 µg/rat) as the first injection, plus saline (1 µL/rat) or SCH23390 (0.25 µg/rat) or sulpiride (0.1 µg/rat), respectively as the second injection.</p>
</sec>
</sec>
<sec id="section16-0269881111405556">
<title>Statistical analysis</title>
<p>One-way analysis of variance (ANOVA) was used for analyzing the effects of different doses of histamine, SKF38393, quinpirole, SCH23390 and sulpiride by themselves, and conjoint administrations of dopamine receptor agonists and antagonists on anxiety-like behaviors. Two-way ANOVA was used for evaluation of interactions between histamine with dopamine receptors agents. Following a significant <italic>p</italic>-value, post hoc analyses (Tukey’s test) were performed to assess paired groups comparisons. Statistical significance levels of <italic>p</italic> &lt; 0.05 were used throughout.</p>
</sec>
<sec id="section17-0269881111405556">
<title>Histology</title>
<p>One day after the testing sessions each rat received an intra-BLA injection of 0.5 µL/side of a methylene blue dye (1%), and approximately 5–10 min later the animal was decapitated and its brain was removed. Brains were fixed in a 10% formalin solution for 5 days and verified for dye extensions in the BLA according to <xref ref-type="bibr" rid="bibr26-0269881111405556">Paxinos and Watson (2007)</xref>. Only data from animals with correct cannulae implants were included in the statistical analyses. Cannulae placements with spread of the dye within 1 mm of the intended site were considered to be correct. Sixteen rats implanted in the BLA were discarded due to incorrect cannula placements and substituted by some other animals, so the final number of animals was eight per each experimental group. <xref ref-type="fig" rid="fig1-0269881111405556">Figure 1</xref> shows a representative histological section of a typical correct cannula placement in the BLA, which was compared with <xref ref-type="bibr" rid="bibr26-0269881111405556">Paxinos and Watson (2007)</xref>.</p>
<fig id="fig1-0269881111405556" position="float">
<label>Figure 1.</label>
<caption><p>A representative coronal section from a rat brain (−2.4 posterior to the bregma), showing the extension of the area reached by the dye infusions in the basolateral amygdala (left side), compared with the related section from <xref ref-type="bibr" rid="bibr26-0269881111405556">Paxinos and Watson (2007)</xref> (right side. Reproduced from <xref ref-type="bibr" rid="bibr26-0269881111405556">Paxinos G and Watson C (2007)</xref> <italic>The Rat Brain in Streretaxic Coordinates, 6th edition</italic> with permission from Elsevier).</p></caption>
<graphic xlink:href="10.1177_0269881111405556-fig1.tif"/>
</fig>
</sec>
</sec>
<sec id="section18-0269881111405556" sec-type="results">
<title>Results</title>
<sec id="section19-0269881111405556">
<title>Intra-BLA injection of histamine induced anxiogenic-like effects in the elevated plus maze</title>
<p><xref ref-type="fig" rid="fig2-0269881111405556">Figure 2</xref> shows the effects of intra-BLA injections of histamine on anxiety-like behaviors in the elevated plus maze. One-way ANOVA revealed that histamine altered %OAT (<italic>F</italic> (4, 35) = 27.66, <italic>p</italic> &lt; 0.001), and %OAE (<italic>F</italic> (4, 35) = 8.47, <italic>p</italic> &lt; 0.001), but caused no change in motor activity (<italic>F</italic> (4, 35) = 0.34, NS). Post hoc comparisons indicated that intra-BLA injections of histamine decreased %OAT at doses of 2.5, 5 and 7.5 µg/rat and %OAE at doses of 5 and 7.5 µg/rat, suggesting that histamine produced anxiogenic-like effects.</p>
<fig id="fig2-0269881111405556" position="float">
<label>Figure 2.</label>
<caption><p>The effect of intra-BLA injections of histamine on anxiety-like behaviors in elevated plus maze. Five groups of animals received intra-amygdala injections of saline or histamine at the different doses (1, 2.5, 5 and 7.5 µg/rat). Each bar represents mean ± SEM (<italic>n</italic> = 8) for %OAT (panel A), %OAE (panel B) and motor activity (panel C). *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01 and ***<italic>p</italic> &lt; 0.001 compared with the saline control group in panels A or B.</p></caption>
<graphic xlink:href="10.1177_0269881111405556-fig2.tif"/>
</fig>
</sec>
<sec id="section20-0269881111405556">
<title>Intra-BLA administrations of dopamine D1 and D2 receptor agonists induced anxiogenic-like effects in the elevated plus maze</title>
<p><xref ref-type="fig" rid="fig3-0269881111405556">Figure 3</xref> shows the effects of intra-BLA administration of the dopamine D1 and D2 receptor agonists, SKF38393 and quinpirole, respectively, on anxiety-like behaviors in the elevated plus maze. One-way ANOVA revealed that intra-BLA administration of SKF38393 altered %OAT (<italic>F</italic> (3, 28) = 8.73, <italic>p</italic> &lt; 0.001), but not %OAE (<italic>F</italic> (3, 28) = 1.53, NS), and motor activity (<italic>F</italic> (3, 28) = 2.01, NS). Post hoc test showed that SKF38393 at a dose of 0.25 µg/rat decreased %OAT, so produced an anxiogenic-like effect.</p>
<fig id="fig3-0269881111405556" position="float">
<label>Figure 3.</label>
<caption><p>The effects of intra-BLA injections of SKF38393 and quinpirole on anxiety-like behaviors. Four groups of animals received saline (1 µL/rat) or SKF38393 at different doses (0.05, 0.125 and 0.25 µg/rat). The other four groups of rats received saline (1 µL/rat) or quinpirole at different doses (0.01, 0.03 and 0.05 µg/rat). Each bar represents mean ± SEM (<italic>n</italic> = 8) for %OAT (panel A), %OAE (panel B) and motor activity (panel C). <italic>***p</italic> &lt; 0.001 compared with the relative saline control group in the panel A. +++<italic>p</italic> &lt; 0.001 compared with the relative saline control group in the panel A.</p></caption>
<graphic xlink:href="10.1177_0269881111405556-fig3.tif"/>
</fig>
<p>One-way ANOVA also showed that intra-BLA injections of quinpirole altered %OAT (<italic>F</italic> (3, 28) = 31.26, <italic>p</italic> &lt; 0.01), but not %OAE (<italic>F</italic> (3, 28) = 1.57, NS), and motor activity (<italic>F</italic> (3, 28) = 1.56, NS). Post hoc comparisons showed that quinpirole at doses of 0.03 and 0.05 µg/rat decreased %OAT, and therefore produced an anxiogenic-like effect (<xref ref-type="fig" rid="fig3-0269881111405556">Figure 3</xref>).</p>
</sec>
<sec id="section21-0269881111405556">
<title>Intra-BLA administrations of dopamine D1 and D2 receptor antagonists induced anxiolytic-like effects in the elevated plus maze</title>
<p><xref ref-type="fig" rid="fig4-0269881111405556">Figure 4</xref> shows the effects of intra-BLA administrations of the dopamine D1 and D2 receptor antagonists, SCH23390 and sulpiride, respectively, on anxiety-like behaviors in the elevated plus maze. One-way ANOVA revealed that intra-BLA administrations of SCH23390 altered %OAT (<italic>F</italic> (3, 28) = 9.46, <italic>p</italic> &lt; 0.001), but not %OAE (<italic>F</italic> (3, 28) = 0.96, NS), and motor activity (<italic>F</italic> (3, 28) = 0.51, NS). Post hoc comparisons showed that SCH23393 at doses of 0.5 and 1 µg/rat increased %OAT, suggesting an anxiolytic-like effect induced by the drug.</p>
<fig id="fig4-0269881111405556" position="float">
<label>Figure 4.</label>
<caption><p>The effects of intra-BLA injections of SCH23390 and sulpiride on anxiety-like behaviors. Four groups of animals received saline (1 µL/rat) or SCH23390 at different doses (0.25, 0.5 and 1 µg/rat). The other four groups of rats received vehicle (1 µL/rat) or sulpiride at different doses (0.1, 0.3 and 0.5 µg/rat). Each bar represents mean ± SEM (<italic>n</italic> = 8) for %OAT (panel A), %OAE (panel B) and motor activity (panel C). <italic>**p</italic> &lt; 0.01 when compared with the saline control group in the panel A. +<italic>p</italic> &lt; 0.05 and ++<italic>p</italic> &lt; 0.01 compared with the vehicle control group in the panel A. +++<italic>p</italic> &lt; 0.001 when compared with the relative vehicle control group in the panel B.</p></caption>
<graphic xlink:href="10.1177_0269881111405556-fig4.tif"/>
</fig>
<p>One-way ANOVA also showed that intra-BLA injections of sulpiride altered %OAT (<italic>F</italic> (3, 28) = 5.92, <italic>p</italic> &lt; 0.01) and %OAE (<italic>F</italic> (3, 28) = 11.76, <italic>p</italic> &lt; 0.001), but not motor activity (<italic>F</italic> (3, 28) = 1.34, NS). Post hoc comparisons showed that sulpiride at doses of 0.3 and 0.5 µg/rat increased %OAT and %OAE, suggesting an anxiolytic-like effect for the drug (<xref ref-type="fig" rid="fig4-0269881111405556">Figure 4</xref>).</p>
</sec>
<sec id="section22-0269881111405556">
<title>Intra-BLA administrations of dopamine D1 or D2 receptor antagonists prevented the anxiogenic-like effects induced by their respective antagonists in the elevated plus maze</title>
<p>The left panels of <xref ref-type="fig" rid="fig5-0269881111405556">Figure 5</xref> indicate the influence of intra-BLA injections of a silent dose of SCH23390 (0.25 µg/rat) on the effect of higher doses of SKF38393 (0.125 and 0.25 µg/rat) on anxiety-like behaviors. One-way ANOVA showed that conjoint intra-BLA administration of SCH23390 and SKF38393 did not alter anxiety-like parameters (for %OAT, <italic>F</italic> (2, 21) = 1.54, NS; for %OAE, <italic>F</italic> (2, 21) = 0.84, NS; and for motor activity, <italic>F</italic> (2, 21) = 0.35, NS). Right panels of <xref ref-type="fig" rid="fig5-0269881111405556">Figure5</xref> show the influence of intra-BLA injections of a silent dose of sulpiride (0.1 µg/rat) on the effect of higher doses of quinpirole (0.03 and 0.05 µg/rat) on anxiety-like behaviors. One-way ANOVA showed that intra-BLA administration of sulpiride before quinpirole either had no effect or little effect on anxiety-like behaviors (for %OAT, <italic>F</italic> (2, 21) = 4.94, <italic>p</italic> &lt; 0.05; for %OAE, <italic>F</italic> (2, 21) = 0.65, NS; for motor activity, <italic>F</italic> (2, 21) = 0.32, NS). These results showed that intra-BLA administrations of dopamine D1 and D2 receptor antagonists prevented the anxiogenic-like effects induced by their agonists, supporting the idea that stimulation of D1 or D2 receptors in the BLA induces changes in anxiety.</p>
<fig id="fig5-0269881111405556" position="float">
<label>Figure 5.</label>
<caption><p>The Effects of conjoint intra-BLA injections of dopamine receptors antagonists and agonists on anxiety-like behaviors. Three groups of the animals received intra-BLA injections of SCH23390 (0.25 µg/rat) plus saline or SKF38393 (0.125 or 0.25 µg/rat). The other three groups received intra-BLA injections of sulpiride (0.1 µg/rat) plus saline or quinpirole (0.03 or 0.05 µg/rat). Each bar represents mean ± SEM (<italic>n</italic> = 8) for %OAT (panel A), %OAE (panel B) and motor activity (panel C). +<italic>p</italic> &lt; 0.05 when compared with the relative saline control group in panel A.</p></caption>
<graphic xlink:href="10.1177_0269881111405556-fig5.tif"/>
</fig>
</sec>
<sec id="section23-0269881111405556">
<title>Interaction between histamine and dopamine D1 and D2 receptor agonists on anxiety-like behaviors in the elevated plus maze</title>
<p><xref ref-type="fig" rid="fig6-0269881111405556">Figure 6</xref> indicates the influence of conjoint intra-BLA injections of a silent dose of SKF38393 (0.05 µg/rat) or quinpirole (0.01 µg/rat) with lower doses of histamine (1 and 2.5 mg/kg) on anxiety-like behaviors. First, we examined interactions between SKF38393, as factor A with two levels, and histamine, as factor B with three levels, on anxiety-like behaviors. Two-way ANOVA showed a significant main effect of SKF38393 (for %OAT, <italic>F</italic> (1, 42) = 6.11, <italic>p</italic> &lt; 0.05; for %OAE, <italic>F</italic> (1, 42) = 52.75, <italic>p</italic> &lt; 0.001; for motor activity <italic>F</italic> (1, 42) = 5.06, <italic>p</italic> &lt; 0.05), but not a significant main effect for histamine (for %OAT, <italic>F</italic> (2, 42) = 2.14, NS; for %OAE, <italic>F</italic> (2, 42) = 2.27, NS; for motor activity, <italic>F</italic> (2, 42) = 2.45, NS). Two-way ANOVA also revealed an interaction between SKF38393 and histamine on anxiety-like parameters (for %OAT, <italic>F</italic> (2, 42) = 8.14, <italic>p</italic> &lt; 0.01; for %OAE, <italic>F</italic> (2, 42) = 4.5, <italic>p</italic> &lt; 0.05; but not for motor activity, <italic>F</italic> (2, 42) = 0.92, NS). Post hoc analyses with Tukey’s test showed that conjoint administrations of SKF38393 and histamine into the BLA induced an anxiolytic-like effect.</p>
<fig id="fig6-0269881111405556" position="float">
<label>Figure 6.</label>
<caption><p>The effects of intra-BLA co-administration of SKF38393 or quinpirole with histamine on anxiety-like behaviors. Three groups of rats received intra-BLA injections of saline-saline or saline-histamine (1 and 2.5 µg/rat). The other three groups received intra-BLA injections of SKF38393 (0.05 µg/rat) plus either saline (SKF-saline) or histamine (SKF-histamine). The last three groups received intra-BLA injections of quinpirole (0.01 µg/rat) plus either saline (quinpirole-saline) or histamine (quinpirole-histamine). Each bar represents mean ± SEM (<italic>n</italic> = 8) for %OAT (panel A), %OAE (panel B) and motor activity (panel C). *<italic>p</italic> &lt; 0.05 compared with saline-saline control group in panel A. +<italic>p</italic> &lt; 0.05 compared with the respective saline-histamine (2.5 µg/rat) group in panel A. ++<italic>p</italic> &lt; 0.01 and +++<italic>p</italic> &lt; 0.001 when compared with the respective saline-histamine group in the panel B. ##<italic>p</italic> &lt; 0.01 when compared with the respective saline-saline or saline-histamine group in panel B.</p></caption>
<graphic xlink:href="10.1177_0269881111405556-fig6.tif"/>
</fig>
<p>Second, we examined conjoint intra-BLA injections of quinpirole, as factor A with two levels, and histamine, as factor B with three levels, on anxiety-like behaviors (<xref ref-type="fig" rid="fig6-0269881111405556">Figure 6</xref>). Analysis of data with two-way ANOVA revealed a significant main effect for quinpirole (for %OAT, <italic>F</italic> (1, 42) = 29.13, <italic>p</italic> &lt; 0.001; for %OAE, <italic>F</italic> (1, 42) = 25.09, <italic>p</italic> &lt; 0.001; but not for motor activity, <italic>F</italic> (1, 42) = 3.61, NS). Two-way ANOVA also revealed a significant main effect of histamine (for %OAT, <italic>F</italic> (2, 42) = 14.37, <italic>p</italic> &lt; 0.001; for %OAE, <italic>F</italic> (2, 42) = 6.15, <italic>p</italic> &lt; 0.01; but not for motor activity, <italic>F</italic> (2, 42) = 0.91, NS). An interaction between quinpirole and histamine in %OAT was also observed (<italic>F</italic> (2, 42) = 15.79, <italic>p</italic> &lt; 0.001), but not in %OAE (<italic>F</italic> (2, 42) = 2.94, NS), and motor activity (<italic>F</italic> (2, 42) = 0.19, NS). Post hoc analyses with Tukey’s test showed that conjoint intra-BLA administrations of quinpirole with histamine at a dose of 1 µg/rat compared with the saline-histamine group decreased %OAT, while in combination with histamine at a dose of 2 µg/rat had no effect on %OAT. In addition, intra-BLA injections of quinpirole along with histamine at a dose of 1 µg/rat had no effect on %OAE, while in combination with histamine at a dose of 2 µg/rat increased %OAE (<xref ref-type="fig" rid="fig6-0269881111405556">Figure 6</xref>).</p>
</sec>
<sec id="section24-0269881111405556">
<title>Interaction between histamine and dopamine D1 and D2 receptor antagonists on anxiety-like behaviors in the elevated plus maze</title>
<p><xref ref-type="fig" rid="fig7-0269881111405556">Figure 7</xref> indicates the influence of intra-BLA injections of a silent dose of SCH23390 (0.25 µg/rat) or sulpiride (0.1 µg/rat) on the effect of higher doses of histamine (2.5, 5 and 7.5 µg/rat) on anxiety-like behaviors. As a two-factor model, we examined interaction between SCH23390, as factor A with two levels, and histamine, as factor B with four levels, on anxiety-like behaviors. Two-way ANOVA showed a significant main effect for SCH23390 in %OAT and %OAE (for %OAT, <italic>F</italic> (1, 56) = 34.42, <italic>p</italic> &lt; 0.001; for %OAE, <italic>F</italic> (1, 56) = 55.22, <italic>p</italic> &lt; 0.001), but not in motor activity (<italic>F</italic> (1, 56) = 0.04, NS). Two-way ANOVA also revealed a significant main effect for histamine in %OAT (<italic>F</italic> (3, 56) = 26.58, <italic>p</italic> &lt; 0.001), but not in %OAE and motor activity (for %OAE, <italic>F</italic> (3, 56) = 0.59, NS; and for motor activity, <italic>F</italic> (3, 56) = 1.35, NS). Two-way ANOVA also indicated an interaction between SCH23390 and histamine in %OAT (<italic>F</italic> (3, 56) = 3.31, <italic>p</italic> &lt; 0.05), but not in %OAE and motor activity (for %OAE, <italic>F</italic> (3, 56) = 0.41, NS; and for motor activity, <italic>F</italic> (3, 56) = 0.02, NS). Post hoc analyses with Tukey’s test showed that conjoint administrations of SCH23390 and histamine into the BLA induced lesser anxiogenic-like effects compared with saline-histamine groups.</p>
<fig id="fig7-0269881111405556" position="float">
<label>Figure 7.</label>
<caption><p>The effects of intra-BLA co-administration of SCH23390 or sulpiride with histamine on anxiety-like behaviors. Three groups of rats received intra-BLA injections of saline-saline or saline-histamine at different doses (1 and 2.5 µg/rat). The other three groups received intra-BLA injections of SCH23390 (0.25 µg/rat) plus either saline (SCH-saline) or histamine (SCH-histamine). The last three groups received intra-BLA injections of sulpiride (0.1 µg/rat) plus either saline (sulpiride-saline) or histamine (sulpiride-histamine). Each bar represents mean ± SEM (<italic>n</italic> = 8) for %OAT (panel A), %OAE (panel B), and motor activity (panel C). **<italic>p</italic> &lt; 0.01 and ***<italic>p</italic> &lt; 0.001 compared with saline-saline control group in the panel A. +<italic>p</italic> &lt; 0.05 and ++<italic>p</italic> &lt; 0.01 when compared with the respective saline-histamine group in panel A. ###<italic>p</italic> &lt; 0.001 compared with the respective saline-histamine group in panel A. +<italic>p</italic> &lt; 0.05 and ++<italic>p</italic> &lt; 0.01 when compared with the respective saline-saline or saline-histamine groups in panel B.</p></caption>
<graphic xlink:href="10.1177_0269881111405556-fig7.tif"/>
</fig>
<p>Interaction between sulpiride and histamine was also examined with conjoint intra-BLA injections of sulpiride as factor A with two levels and histamine as factor B with four levels, on anxiety-like behaviors (<xref ref-type="fig" rid="fig7-0269881111405556">Figure 7</xref>). Analysis of data with two-way ANOVA revealed a significant main effect for sulpiride in %OAT and %OAE (for %OAT, <italic>F</italic> (1, 56) = 23.2, <italic>p</italic> &lt; 0.001; for %OAE, <italic>F</italic> (1, 56) = 14.31, <italic>p</italic> &lt; 0.001); but not in motor activity (<italic>F</italic> (1, 56) = 0.59, NS). Two-way ANOVA also revealed a significant main effect for histamine in %OAT (<italic>F</italic> (3, 56) = 17.98, <italic>p</italic> &lt; 0.001), but not in %OAE (<italic>F</italic> (3, 56) = 1.77, NS; and motor activity, <italic>F</italic> (3, 56) = 0.66, NS). An interaction between sulpiride and histamine in %OAT was also observed (<italic>F</italic> (3, 56) = 3.89, <italic>p</italic> &lt; 0.05), but not in %OAE (<italic>F</italic> (2, 42) = 2.94, NS), and motor activity (<italic>F</italic> (3, 56) = 0.67, NS). Post hoc analyses with Tukey’s test showed that administration of sulpiride into the BLA along with histamine at dose of 5 µg/rat abolished the decrease in %OAT. In addition, intra-BLA injections of sulpiride along with histamine also showed a tendency to increase %OAE but no significant effect was observed.</p>
</sec>
</sec>
<sec id="section25-0269881111405556" sec-type="discussion">
<title>Discussion</title>
<p>The results of the present experiments indicate that intra-BLA administration of histamine decreased percent preference for open arm time (%OAT) and open arm entries (%OAE) in the elevated plus maze, indicating an anxiogenic-like effect for the drug. In line with the present results, an anxiogenic-like effect for histamine has been reported in various brain areas. In particular, it has been reported that intra-cerebroventricular (<xref ref-type="bibr" rid="bibr50-0269881111405556">Zarrindast et al., 2005c</xref>), intra-ventral hippocampus (<xref ref-type="bibr" rid="bibr45-0269881111405556">Zarrindast et al., 2010a</xref>), intra-lateral septum (<xref ref-type="bibr" rid="bibr53-0269881111405556">Zarrindast et al., 2008b</xref>), intra-central amygdala (<xref ref-type="bibr" rid="bibr46-0269881111405556">Zarrindast et al., 2005a</xref>), and intra-BLA (<xref ref-type="bibr" rid="bibr14-0269881111405556">Hajizadeh Moghaddam et al., 2008</xref>; <xref ref-type="bibr" rid="bibr46-0269881111405556">Zarrindast et al., 2005a</xref>) injections of histamine induce anxiogenic-like effects in the elevated plus maze in rat. <xref ref-type="bibr" rid="bibr21-0269881111405556">Malmberg-Aiello et al. (2002)</xref> reported that activation of histamine H1 receptors reduced the time spent in the lighted compartment of light/dark box, suggesting an anxiogenic-like effect for histamine H1 receptors. Conversely, <xref ref-type="bibr" rid="bibr52-0269881111405556">Zarrindast et al. (2006)</xref> also reported that intra-dorsal hippocampus administration of histamine induced an anxiolytic-like effect in the elevated plus maze.</p>
<p>It has been postulated that excitability levels of the BLA are closely involved with anxiety, which is mainly regulated by GABAergic inhibitory interneurons in the BLA (<xref ref-type="bibr" rid="bibr5-0269881111405556">Bueno et al., 2005</xref>; <xref ref-type="bibr" rid="bibr24-0269881111405556">Park et al., 2011</xref>; <xref ref-type="bibr" rid="bibr34-0269881111405556">Saldivar-Gonzalez et al., 2003</xref>). Therefore, the anxiogenic-like effect of histamine in the present study may result from its effect on the excitability level of the BLA. It has been shown that β-adrenergic receptors and D1 dopamine receptors, which are both coupled to the same signaling cascade as the histamine H2 receptor, are located on axon terminals and facilitate the release of glutamate in the amygdala (<xref ref-type="bibr" rid="bibr16-0269881111405556">Huang et al., 1996</xref>). Recent biochemical experiments also support such a presynaptic role for H2 receptors in the control of noradrenaline release (<xref ref-type="bibr" rid="bibr40-0269881111405556">Timm et al., 1998</xref>). A similar localization and action for H2 receptors may also be present in the BLA, and it is possible that histamine, through activation of histamine H2 receptors, excites projection neurons from the BLA. On the other hand, intra-BLA injections of histamine may inhibit release of GABA in the BLA, and so indirectly increase the excitability level of the BLA neurons. In support of this suggestion it has been shown that histamine, through histamine H3 receptors, inhibits the release of other neurotransmitters, including GABA (for review see <xref ref-type="bibr" rid="bibr4-0269881111405556">Brown et al., 2001</xref>).</p>
<p>The results of the present study also indicate that intra-BLA administration of dopamine D1 and D2 agonists, SKF38393 and quinpirole, respectively, decreased %OAT with no significant change in %OAE and motor activity in the elevated plus maze. Therefore, the present results suggest that intra-BLA injections of SKF38393 and quinpirole exert an anxiogenic-like effect. In contrast, blockade of the BLA dopamine D1 receptors with SCH23390 increased %OAT without significant change in %OAE and motor activity. Intra-BLA injections of the dopamine D2 receptor antagonist, sulpiride, also increased both of %OAT and %OAE with no change in motor activity, suggesting an anxiolytic-like effect for both drugs. It is possible that the activation of dopamine receptors within the BLA increased the state of excitability of the BLA, and so induced the anxiogenic-like effects of the elevated plus maze. Conversely, blockade of dopamine receptors in the BLA may have the opposite effects, and therefore induce anxiolytic-like effects. However, full elucidation of the exact mechanism of the dopamine receptors action in the BLA on anxiety-like behaviors needs further investigation. According to these results, it can be suggested that dopamine receptors within the BLA are involved in modulating anxiety-like behaviors. In support of this suggestion, combination treatments of dopamine receptors agents into the BLA revealed that anxiogenic-like effects induced by dopamine receptor agonists were prevented by their respective antagonists, providing further support for the involvement of dopamine receptors in the BLA in anxiety.</p>
<p>It has been reported that blockade of dopamine D1 receptors by systemic administration of SCH23390 causes no effects on anxiety-like behaviors using either the elevated plus maze test in mice (<xref ref-type="bibr" rid="bibr32-0269881111405556">Rodgers et al., 1994</xref>), or the ultrasonic vocalization paradigm in rats (<xref ref-type="bibr" rid="bibr2-0269881111405556">Bartoszyk, 1998</xref>). In contrast, systemic administration of SCH23390 has been shown to inhibit acquisition of conditioned freezing in rat, which represents an anxiolytic-like effect for the drug (<xref ref-type="bibr" rid="bibr9-0269881111405556">de Oliveira et al., 2006</xref>; <xref ref-type="bibr" rid="bibr18-0269881111405556">Inoue et al., 2005</xref>). On the other hand, blockade of D2-like dopamine receptors by systemic administration of sulpiride in mice induced an anxiolytic-like effect in a conditioned fear task (<xref ref-type="bibr" rid="bibr28-0269881111405556">Ponnusamy et al., 2005</xref>) and the elevated plus maze (<xref ref-type="bibr" rid="bibr32-0269881111405556">Rodgers et al., 1994</xref>). In line with the present results for SCH23390, it has been also demonstrated that intra-amygdaloid injections of SCH233390 exert an anxiolytic-like effect in the white and black box test of anxiety in rat (<xref ref-type="bibr" rid="bibr8-0269881111405556">de la Mora et al., 2005</xref>). In addition, microinjections of SCH23390 and sulpiride into the CeA caused no significant change in anxiety-like behaviors in the elevated plus maze (<xref ref-type="bibr" rid="bibr30-0269881111405556">Rezayof et al., 2009</xref>). It has been recently reported that activation of dopamine receptors by intra-ventral hippocampal injection of apomorphine, a D1/D2 dopamine receptor agonist, induces anxiogenic-like effects, while SCH23390 and sulpiride did not elicit any response (<xref ref-type="bibr" rid="bibr47-0269881111405556">Zarrindast et al., 2010b</xref>). According to the above-cited data there is a discrepancy in the effects of dopamine receptor agents on anxiety-like behaviors, which may result from the different routes of administration, sites of injection, anxiety assessing tests and/or different subjects.</p>
<p>The results of the present study also show that conjoint intra-BLA administration of an ineffective dose of SKF38393 with lower doses of histamine into the BLA caused anxiolytic-like effects. Quinpirole in combination with histamine at dose of 1 µg/rat induced an anxiogenic-like effect, while in combination with a moderate dose of histamine (2.5 µg/rat) induced an anxiolytic-like effect. It is difficult to interpret the anxiolytic-like effects of these combination treatments, as each of the drugs had anxiogenic-like effects on its own. Nevertheless, it is possible that in case of these two injections into the BLA, the overall excitability of the BLA neurons would decrease, and so induce anxiolytic-like effects. It is possible that in combination, treatments of dopamine receptor agonists with histamine into the BLA further complicate interactions on pre-synaptic dopamine receptors located on glutamatergic terminals, and post-synaptic histamine and dopamine receptors located on other neurons such as GABAergic interneurons and glutamatergic projection neurons may account for anxiolytic-like effects (see introduction for review anatomical connection within the BLA). It has been reported that injection of quinpirole into the VTA before the test session significantly reduced fear-potentiated startle as an index of anxiety, which may be the result of an action on the VTA dopamine D2 presynaptic autoreceptors that decreases dopamine levels in terminal fields of the mesocorticolimbic pathway (<xref ref-type="bibr" rid="bibr10-0269881111405556">de Oliveira et al., 2009</xref>). There is a possibility that the effect of quinpirole in the present study on anxiogenic-like effects of histamine may be due, at least partly, to affecting the dopamine D2 presynaptic receptors in the amygdala, and decreasing the excitability of the BLA neurons. However, when the effects of histamine are challenged with dopamine agents, besides the conjoint effects of both drugs on anxiety-like behaviors, other factors might have contributed to the results, such as volume of injections (1.0 µL at each side), lesions caused by two injections into each BLA, time between injections, and so on.</p>
<p>The results of the present study also indicated that, when an ineffective dose of SCH23390 or sulpiride was co-administered along with higher doses of histamine into the BLA, the anxiogenic-like effects of histamine were prevented. The results obtained with conjoint administration of dopamine antagonists and histamine may further support that the effect of histamine in the BLA on excitability of the BLA and anxiety-like behaviors is mediated via other neurotransmitter systems, including dopamine. Taking these results together, it can be concluded that dopamine receptors in the BLA are involved in anxiogenic-like effects of histamine.</p>
</sec>
</body>
<back>
<sec id="section26-0269881111405556">
<title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="section27-0269881111405556">
<title>Conflicts of interest</title>
<p>The authors declare that they have no conflict of interest.</p>
</sec>
<sec id="section28-0269881111405556">
<title>Acknowledgements</title>
<p>We thank Shaho Zarei (Department of Statistics, University of Kurdistan) for his comments on statistics analyses.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amaral</surname><given-names>DG</given-names></name>
<name><surname>Corbett</surname><given-names>BA</given-names></name>
</person-group> (<year>2003</year>) <article-title>The amygdala, autism and anxiety</article-title>. <source>Novartis Found Symp</source> <volume>251</volume>: <fpage>177</fpage>–<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr2-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartoszyk</surname><given-names>GD</given-names></name>
</person-group> (<year>1998</year>) <article-title>Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors</article-title>. <source>Life Sci</source> <volume>62</volume>: <fpage>649</fpage>–<lpage>663</lpage>.</citation>
</ref>
<ref id="bibr3-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brandao</surname><given-names>ML</given-names></name>
<name><surname>Anseloni</surname><given-names>VZ</given-names></name>
<name><surname>Pandossio</surname><given-names>JE</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Neurochemical mechanisms of the defensive behavior in the dorsal midbrain</article-title>. <source>Neurosci Biobehav Rev</source> <volume>23</volume>: <fpage>863</fpage>–<lpage>875</lpage>.</citation>
</ref>
<ref id="bibr4-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>RE</given-names></name>
<name><surname>Stevens</surname><given-names>DR</given-names></name>
<name><surname>Haas</surname><given-names>HL</given-names></name>
</person-group> (<year>2001</year>) <article-title>The physiology of brain histamine</article-title>. <source>Prog Neurobiol</source> <volume>63</volume>: <fpage>637</fpage>–<lpage>672</lpage>.</citation>
</ref>
<ref id="bibr5-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bueno</surname><given-names>CH</given-names></name>
<name><surname>Zangrossi</surname><given-names>H</given-names><suffix>Jr</suffix></name>
<name><surname>Viana</surname><given-names>MB</given-names></name>
</person-group> (<year>2005</year>) <article-title>The inactivation of the basolateral nucleus of the rat amygdala has an anxiolytic effect in the elevated T-maze and light/dark transition tests</article-title>. <source>Braz J Med Biol Res</source> <volume>38</volume>: <fpage>1697</fpage>–<lpage>1701</lpage>.</citation>
</ref>
<ref id="bibr6-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coco</surname><given-names>ML</given-names></name>
<name><surname>Kuhn</surname><given-names>CM</given-names></name>
<name><surname>Ely</surname><given-names>TD</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>Selective activation of mesoamygdaloid dopamine neurons by conditioned stress: attenuation by diazepam</article-title>. <source>Brain Res</source> <volume>590</volume>: <fpage>39</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr7-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>M</given-names></name>
<name><surname>Rainnie</surname><given-names>D</given-names></name>
<name><surname>Cassell</surname><given-names>M</given-names></name>
</person-group> (<year>1994</year>) <article-title>Neurotransmission in the rat amygdala related to fear and anxiety</article-title>. <source>Trends Neurosci</source> <volume>17</volume>: <fpage>208</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr8-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de la Mora</surname><given-names>MP</given-names></name>
<name><surname>Cardenas-Cachon</surname><given-names>L</given-names></name>
<name><surname>Vazquez-Garcia</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Anxiolytic effects of intra-amygdaloid injection of the D1 antagonist SCH23390 in the rat</article-title>. <source>Neurosci Lett</source> <volume>377</volume>: <fpage>101</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr9-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Oliveira</surname><given-names>AR</given-names></name>
<name><surname>Reimer</surname><given-names>AE</given-names></name>
<name><surname>Brandao</surname><given-names>ML</given-names></name>
</person-group> (<year>2006</year>) <article-title>Dopamine D2 receptor mechanisms in the expression of conditioned fear</article-title>. <source>Pharmacol Biochem Behav</source> <volume>84</volume>: <fpage>102</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr10-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Oliveira</surname><given-names>AR</given-names></name>
<name><surname>Reimer</surname><given-names>AE</given-names></name>
<name><surname>Brandao</surname><given-names>ML</given-names></name>
</person-group> (<year>2009</year>) <article-title>Role of dopamine receptors in the ventral tegmental area in conditioned fear</article-title>. <source>Behav Brain Res</source> <volume>199</volume>: <fpage>271</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr11-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greba</surname><given-names>Q</given-names></name>
<name><surname>Gifkins</surname><given-names>A</given-names></name>
<name><surname>Kokkinidis</surname><given-names>L</given-names></name>
</person-group> (<year>2001</year>) <article-title>Inhibition of amygdaloid dopamine D2 receptors impairs emotional learning measured with fear-potentiated startle</article-title>. <source>Brain Res</source> <volume>899</volume>: <fpage>218</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr12-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haas</surname><given-names>H</given-names></name>
<name><surname>Panula</surname><given-names>P</given-names></name>
</person-group> (<year>2003</year>) <article-title>The role of histamine and the tuberomamillary nucleus in the nervous system</article-title>. <source>Nat Rev Neurosci</source> <volume>4</volume>: <fpage>121</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr13-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haas</surname><given-names>HL</given-names></name>
<name><surname>Sergeeva</surname><given-names>OA</given-names></name>
<name><surname>Selbach</surname><given-names>O</given-names></name>
</person-group> (<year>2008</year>) <article-title>Histamine in the nervous system</article-title>. <source>Physiol Rev</source> <volume>88</volume>: <fpage>1183</fpage>–<lpage>1241</lpage>.</citation>
</ref>
<ref id="bibr14-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hajizadeh Moghaddam</surname><given-names>A</given-names></name>
<name><surname>Roohbakhsh</surname><given-names>A</given-names></name>
<name><surname>Rostami</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>GABA and histamine interaction in the basolateral amygdala of rats in the plus-maze test of anxiety-like behaviors</article-title>. <source>Pharmacology</source> <volume>82</volume>: <fpage>59</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr15-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Homberg</surname><given-names>JR</given-names></name>
<name><surname>van den Akker</surname><given-names>M</given-names></name>
<name><surname>Raaso</surname><given-names>HS</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Enhanced motivation to self-administer cocaine is predicted by self-grooming behaviour and relates to dopamine release in the rat medial prefrontal cortex and amygdala</article-title>. <source>Eur J Neurosci</source> <volume>15</volume>: <fpage>1542</fpage>–<lpage>1550</lpage>.</citation>
</ref>
<ref id="bibr16-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>CC</given-names></name>
<name><surname>Hsu</surname><given-names>KS</given-names></name>
<name><surname>Gean</surname><given-names>PW</given-names></name>
</person-group> (<year>1996</year>) <article-title>Isoproterenol potentiates synaptic transmission primarily by enhancing presynaptic calcium influx via P- and/or Q-type calcium channels in the rat amygdala</article-title>. <source>J Neurosci</source> <volume>16</volume>: <fpage>1026</fpage>–<lpage>1033</lpage>.</citation>
</ref>
<ref id="bibr17-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inglis</surname><given-names>FM</given-names></name>
<name><surname>Moghaddam</surname><given-names>B</given-names></name>
</person-group> (<year>1999</year>) <article-title>Dopaminergic innervation of the amygdala is highly responsive to stress</article-title>. <source>J Neurochem</source> <volume>72</volume>: <fpage>1088</fpage>–<lpage>1094</lpage>.</citation>
</ref>
<ref id="bibr18-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>T</given-names></name>
<name><surname>Izumi</surname><given-names>T</given-names></name>
<name><surname>Li</surname><given-names>XB</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Effect of a dopamine D1/5 receptor antagonist on haloperidol-induced inhibition of the acquisition of conditioned fear</article-title>. <source>Eur J Pharmacol</source> <volume>519</volume>: <fpage>253</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr19-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ito</surname><given-names>C</given-names></name>
<name><surname>Shen</surname><given-names>H</given-names></name>
<name><surname>Toyota</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Effects of the acute and chronic restraint stresses on the central histaminergic neuron system of Fischer rat</article-title>. <source>Neurosci Lett</source> <volume>262</volume>: <fpage>143</fpage>–<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr20-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>LeDoux</surname><given-names>JE</given-names></name>
</person-group> (<year>2000</year>) <article-title>Emotion circuits in the brain</article-title>. <source>Annu Rev Neurosci</source> <volume>23</volume>: <fpage>155</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr21-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malmberg-Aiello</surname><given-names>P</given-names></name>
<name><surname>Ipponi</surname><given-names>A</given-names></name>
<name><surname>Bartolini</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Mouse light/dark box test reveals anxiogenic-like effects by activation of histamine H1 receptors</article-title>. <source>Pharmacol Biochem Behav</source> <volume>71</volume>: <fpage>313</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr22-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Millan</surname><given-names>MJ</given-names></name>
</person-group> (<year>2003</year>) <article-title>The neurobiology and control of anxious states</article-title>. <source>Prog Neurobiol</source> <volume>70</volume>: <fpage>83</fpage>–<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr23-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Panula</surname><given-names>P</given-names></name>
<name><surname>Pirvola</surname><given-names>U</given-names></name>
<name><surname>Auvinen</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>1989</year>) <article-title>Histamine-immunoreactive nerve fibers in the rat brain</article-title>. <source>Neuroscience</source> <volume>28</volume>: <fpage>585</fpage>–<lpage>610</lpage>.</citation>
</ref>
<ref id="bibr24-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>K</given-names></name>
<name><surname>Yi</surname><given-names>JH</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>HCN channel activity-dependent modulation of inhibitory synaptic transmission in the rat basolateral amygdala</article-title>. <source>Biochem Biophys Res Commun</source> <volume>404</volume>: <fpage>952</fpage>–<lpage>957</lpage>.</citation>
</ref>
<ref id="bibr25-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Passani</surname><given-names>MB</given-names></name>
<name><surname>Giannoni</surname><given-names>P</given-names></name>
<name><surname>Bucherelli</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Histamine in the brain: beyond sleep and memory</article-title>. <source>Biochem Pharmacol</source> <volume>73</volume>: <fpage>1113</fpage>–<lpage>1122</lpage>.</citation>
</ref>
<ref id="bibr26-0269881111405556">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Paxinos</surname><given-names>G</given-names></name>
<name><surname>Watson</surname><given-names>C</given-names></name>
</person-group> (<year>2007</year>) <source>The rat brain in stereotaxic coordinates, 6th edition</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Academic Press</publisher-name>.</citation>
</ref>
<ref id="bibr27-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Phelps</surname><given-names>EA</given-names></name>
<name><surname>LeDoux</surname><given-names>JE</given-names></name>
</person-group> (<year>2005</year>) <article-title>Contributions of the amygdala to emotion processing: from animal models to human behavior</article-title>. <source>Neuron</source> <volume>48</volume>: <fpage>175</fpage>–<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr28-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ponnusamy</surname><given-names>R</given-names></name>
<name><surname>Nissim</surname><given-names>HA</given-names></name>
<name><surname>Barad</surname><given-names>M</given-names></name>
</person-group> (<year>2005</year>) <article-title>Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice</article-title>. <source>Learn Mem</source> <volume>12</volume>: <fpage>399</fpage>–<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr29-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Privou</surname><given-names>C</given-names></name>
<name><surname>Knoche</surname><given-names>A</given-names></name>
<name><surname>Hasenohrl</surname><given-names>RU</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>The H1- and H2-histamine blockers chlorpheniramine and ranitidine applied to the nucleus basalis magnocellularis region modulate anxiety and reinforcement related processes</article-title>. <source>Neuropharmacology</source> <volume>37</volume>: <fpage>1019</fpage>–<lpage>1032</lpage>.</citation>
</ref>
<ref id="bibr30-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rezayof</surname><given-names>A</given-names></name>
<name><surname>Hosseini</surname><given-names>SS</given-names></name>
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
</person-group> (<year>2009</year>) <article-title>Effects of morphine on rat behaviour in the elevated plus maze: the role of central amygdala dopamine receptors</article-title>. <source>Behav Brain Res</source> <volume>202</volume>: <fpage>171</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr31-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodgers</surname><given-names>RJ</given-names></name>
<name><surname>Johnson</surname><given-names>NJ</given-names></name>
</person-group> (<year>1995</year>) <article-title>Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety</article-title>. <source>Pharmacol Biochem Behav</source> <volume>52</volume>: <fpage>297</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr32-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodgers</surname><given-names>RJ</given-names></name>
<name><surname>Nikulina</surname><given-names>EM</given-names></name>
<name><surname>Cole</surname><given-names>JC</given-names></name>
</person-group> (<year>1994</year>) <article-title>Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze</article-title>. <source>Pharmacol Biochem Behav</source> <volume>49</volume>: <fpage>985</fpage>–<lpage>995</lpage>.</citation>
</ref>
<ref id="bibr33-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sah</surname><given-names>P</given-names></name>
<name><surname>Faber</surname><given-names>ES</given-names></name>
<name><surname>Lopez De Armentia</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>The amygdaloid complex: anatomy and physiology</article-title>. <source>Physiol Rev</source> <volume>83</volume>: <fpage>803</fpage>–<lpage>834</lpage>.</citation>
</ref>
<ref id="bibr34-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saldivar-Gonzalez</surname><given-names>JA</given-names></name>
<name><surname>Posadas-Andrews</surname><given-names>A</given-names></name>
<name><surname>Rodriguez</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Effect of electrical stimulation of the baso-lateral amygdala nucleus on defensive burying shock probe test and elevated plus maze in rats</article-title>. <source>Life Sci</source> <volume>72</volume>: <fpage>819</fpage>–<lpage>829</lpage>.</citation>
</ref>
<ref id="bibr35-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>T</given-names></name>
<name><surname>Ishigooka</surname><given-names>J</given-names></name>
<name><surname>Watanabe</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Enhancement of delayed release of dopamine in the amygdala induced by conditioned fear stress in methamphetamine-sensitized rats</article-title>. <source>Eur J Pharmacol</source> <volume>435</volume>: <fpage>59</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr36-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Swanson</surname><given-names>LW</given-names></name>
</person-group> (<year>1982</year>) <article-title>The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat</article-title>. <source>Brain Res Bull</source> <volume>9</volume>: <fpage>321</fpage>–<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr37-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Swanson</surname><given-names>LW</given-names></name>
<name><surname>Petrovich</surname><given-names>GD</given-names></name>
</person-group> (<year>1998</year>) <article-title>What is the amygdala?</article-title>. <source>Trends Neurosci</source> <volume>21</volume>: <fpage>323</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr38-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>KM</given-names></name>
<name><surname>Snyder</surname><given-names>SH</given-names></name>
</person-group> (<year>1971</year>) <article-title>Brain histamine: rapid apparent turnover altered by restraint and cold stress</article-title>. <source>Science</source> <volume>172</volume>: <fpage>1037</fpage>–<lpage>1039</lpage>.</citation>
</ref>
<ref id="bibr39-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thiel</surname><given-names>CM</given-names></name>
<name><surname>Schwarting</surname><given-names>RK</given-names></name>
</person-group> (<year>2001</year>) <article-title>Dopaminergic lateralisation in the forebrain: relations to behavioural asymmetries and anxiety in male Wistar rats</article-title>. <source>Neuropsychobiology</source> <volume>43</volume>: <fpage>192</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr40-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Timm</surname><given-names>J</given-names></name>
<name><surname>Marr</surname><given-names>I</given-names></name>
<name><surname>Werthwein</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>H2 receptor-mediated facilitation and H3 receptor-mediated inhibition of noradrenaline release in the guinea-pig brain</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source> <volume>357</volume>: <fpage>232</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr41-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Timothy</surname><given-names>C</given-names></name>
<name><surname>Costall</surname><given-names>B</given-names></name>
<name><surname>Smythe</surname><given-names>JW</given-names></name>
</person-group> (<year>1999</year>) <article-title>Effects of SCH23390 and raclopride on anxiety-like behavior in rats tested in the black-white box</article-title>. <source>Pharmacol Biochem Behav</source> <volume>62</volume>: <fpage>323</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr42-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tzavara</surname><given-names>ET</given-names></name>
<name><surname>Wade</surname><given-names>M</given-names></name>
<name><surname>Nomikos</surname><given-names>GG</given-names></name>
</person-group> (<year>2003</year>) <article-title>Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action</article-title>. <source>J Neurosci</source> <volume>23</volume>: <fpage>9374</fpage>–<lpage>9384</lpage>.</citation>
</ref>
<ref id="bibr43-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshitomi</surname><given-names>I</given-names></name>
<name><surname>Itoh</surname><given-names>Y</given-names></name>
<name><surname>Oishi</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>1986</year>) <article-title>Brain histamine turnover enhanced by footshock</article-title>. <source>Brain Res</source> <volume>362</volume>: <fpage>195</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr44-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zahm</surname><given-names>DS</given-names></name>
<name><surname>Trimble</surname><given-names>M</given-names></name>
</person-group> (<year>2008</year>) <article-title>The dopaminergic projection system, basal forebrain macrosystems, and conditioned stimuli</article-title>. <source>CNS Spectr</source> <volume>13</volume>: <fpage>32</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr45-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Khodarahmi</surname><given-names>P</given-names></name>
<name><surname>Rezayof</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2010a</year>) <article-title>Withdrawal from repeated administration of morphine alters histamine-induced anxiogenic effects produced by intra-ventral hippocampal microinjection</article-title>. <source>J Psychopharmacol</source> <volume>24</volume>: <fpage>881</fpage>–<lpage>889</lpage>.</citation>
</ref>
<ref id="bibr46-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Moghadam</surname><given-names>AH</given-names></name>
<name><surname>Rostami</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2005a</year>) <article-title>The effects of histaminergic agents in the central amygdala of rats in the elevated plus-maze test of anxiety</article-title>. <source>Behav Pharmacol</source> <volume>16</volume>: <fpage>643</fpage>–<lpage>649</lpage>.</citation>
</ref>
<ref id="bibr47-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Naghdi-Sedeh</surname><given-names>N</given-names></name>
<name><surname>Nasehi</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2010b</year>) <article-title>The effects of dopaminergic drugs in the ventral hippocampus of rats in the nicotine-induced anxiogenic-like response</article-title>. <source>Neurosci Lett</source> <volume>475</volume>: <fpage>156</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr48-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Nasehi</surname><given-names>M</given-names></name>
<name><surname>Rostami</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2005b</year>) <article-title>Repeated administration of dopaminergic agents in the dorsal hippocampus and morphine-induced place preference</article-title>. <source>Behav Pharmacol</source> <volume>16</volume>: <fpage>85</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr49-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Rezayof</surname><given-names>A</given-names></name>
<name><surname>Sahraei</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Involvement of dopamine D1 receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat</article-title>. <source>Brain Res</source> <volume>965</volume>: <fpage>212</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr50-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Rostami</surname><given-names>P</given-names></name>
<name><surname>Zarei</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2005c</year>) <article-title>Intracerebroventricular effects of histaminergic agents on morphine-induced anxiolysis in the elevated plus-maze in rats</article-title>. <source>Basic Clin Pharmacol Toxicol</source> <volume>97</volume>: <fpage>276</fpage>–<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr51-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Sarahroodi</surname><given-names>S</given-names></name>
<name><surname>Arzi</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2008a</year>) <article-title>Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behaviour: interaction with the opioid system</article-title>. <source>Behav Pharmacol</source> <volume>19</volume>: <fpage>716</fpage>–<lpage>723</lpage>.</citation>
</ref>
<ref id="bibr52-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Torabi</surname><given-names>M</given-names></name>
<name><surname>Rostami</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>The effects of histaminergic agents in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety</article-title>. <source>Pharmacol Biochem Behav</source> <volume>85</volume>: <fpage>500</fpage>–<lpage>506</lpage>.</citation>
</ref>
<ref id="bibr53-0269881111405556">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zarrindast</surname><given-names>MR</given-names></name>
<name><surname>Valizadegan</surname><given-names>F</given-names></name>
<name><surname>Rostami</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2008b</year>) <article-title>Histaminergic system of the lateral septum in the modulation of anxiety-like behaviour in rats</article-title>. <source>Eur J Pharmacol</source> <volume>583</volume>: <fpage>108</fpage>–<lpage>114</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>